Component therapy to cellular therapy and beyond— a Darwinian approach to transfusion medicine

Snyder, Edward L.

doi:10.1111/j.1537-2995.2008.01859.x

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Darwin's three life choices, adapt, migrate, or die, also apply to the field of TM. It is clear to see that during the past 50 years, adaptation, survival, and expansion is the path that the AABB has chosen 33 . Doubtless, it is the right path for the field and for the patients we serve.…”

Section: Carpe Futurummentioning

confidence: 99%

The emergence of cellular therapy: impact on transfusion medicine

Snyder

Choate

2010

Transfusion

View full text Add to dashboard Cite

Section: Carpe Futurummentioning

confidence: 99%

The emergence of cellular therapy: impact on transfusion medicine

Snyder

Choate

2010

Transfusion

View full text Add to dashboard Cite

“…In the last 30 years, transfusion medicine has evolved from a field focused on blood component therapy and red blood cell serology to include advanced cellular therapies produced by ex vivo expansion [1, 2]. The broadest applications of cellular therapies to date have been in the area of regenerative medicine and have involved ex vivo cultured fibroblasts, keratinocytes, and chondrocytes (reviewed in [3]), but substantial progress has also occurred with cellular therapies involving lymphoid and hematopoietic cells.…”

Section: Introductionmentioning

confidence: 99%

Alternative Blood Products and Clinical Needs in Transfusion Medicine

Whitsett

Vaglio

Grazzini

2012

Stem Cells International

View full text Add to dashboard Cite

The primary focus of national blood programs is the provision of a safe and adequate blood supply. This goal is dependent on regular voluntary donations and a regulatory infrastructure that establishes and enforces standards for blood safety. Progress in ex vivo expansion of blood cells from cell sources including peripheral blood, cord blood, induced pluripotent stem cells, and human embryonic stem cell lines will likely make alternative transfusion products available for clinical use in the near future. Initially, alloimmunized patients and individuals with rare blood types are most likely to benefit from alternative products. However, in developed nations voluntary blood donations are projected to be inadequate in the future as blood usage by individuals 60 years and older increases. In developing nations economic and political challenges may impede progress in attaining self-sufficiency. Under these circumstances, ex vivo generated red cells may be needed to supplement the general blood supply.

show abstract

Optimizing Blood Transfusion Service Delivery across the West African Sub-Region

Erhabor,

O. Akpotuzor,

Yaw Afriyie

et al. 2023

Thalassemia Syndromes - New Insights and Transfusion Modalities

View full text Add to dashboard Cite

The sub-continent of West Africa is made up of 16 countries: Benin, Burkina Faso, Cape Verde, Ghana, Guinea, Guinea-Bissau, Ivory Coast, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, The Gambia and Togo. As of 2018, the population of the sub-continent was estimated at about 381 million. The main challenge associated with blood transfusion service delivery across the sub-region concerns adequacy and safety. In this chapter, we highlighted the challenges associated with the delivery of a quality blood transfusion service in countries in the sub-region including: implementation of component therapy rather than whole blood transfusion, effective cold chain management of blood and blood products, alloimmunization prevention, implementation of column agglutination and automation rather than the convention manual tube method in blood transfusion testing, effective management of major haemorrhage, optimization of screening for transfusion transmissible infections, optimizing blood donation, implementation of universal leucodepletion of blood and blood products, effective management of transfusion-dependent patients, pre-operative planning and management of surgical patients, management of Rhesus D negative pregnancy and women with clinically significant alloantibodies, implementation of haemovigilance system, implementation of alternatives to allogenic blood, availability and use of specialized blood products, optimizing safe blood donation, enhancing blood transfusion safety, operating a quality management system-based blood transfusion service and implementation of non-invasive cell-free foetal DNA testing. There is the urgent need for the implementation of evidence-based best practices in blood transfusion service delivery across the sub-region to allow for excellent, safe, adequate and timely blood transfusion service delivery across the sub-region.

show abstract

Component therapy to cellular therapy and beyond— a Darwinian approach to transfusion medicine

Cited by 3 publications

References 25 publications

The emergence of cellular therapy: impact on transfusion medicine

The emergence of cellular therapy: impact on transfusion medicine

Alternative Blood Products and Clinical Needs in Transfusion Medicine

Optimizing Blood Transfusion Service Delivery across the West African Sub-Region

Contact Info

Product

Resources

About